The cardiotoxicity of anthracyclines and trastuzumab in the treatment of breast cancer have been well elucidated, however there is little information surrounding the cardiovascular impact for more recent novel agents. Susan Dent, MD, FRCPC, Duke University School of Medicine, Durham, NC, discusses the cardiovascular impact of newer novel agents including CDK4/6 inhibitors and immune checkpoint inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.